AriBio's Oral Dementia Drug Shows 'Partial Success' in Phase 3... FDA Approval Uncertain (Comprehensive)
Only patients not taking existing medications saw progression slowed by 31%
No efficacy demonstrated in the overall group of 1,535 patients
Experts: "Without results in the overall group, approval is questionable"
AR1001, an oral Alzheimer's disease drug candidate developed by South Korean biotech company AriBio, achieved only “limited success” in a global Phase 3 trial, demonstrating efficacy only in patients who were not taking existing dementia medications.
In a subgroup of patients, AR1001 slowed the rate of symptom worsening by 31% compared with placebo, meeting the primary goal set by the company in advance. However, it did not produce a meaningful difference from placebo in the overall patient population enrolled in the trial. Since regulators generally place greater weight on results from the overall population, analysts say it remains uncertain whether these results alone will be enough to secure approval from the U.S. Food and Drug Administration (FDA).
Sharon Sha, a professor at Stanford University School of Medicine and the lead investigator for AR1001's clinical trial, presented the 52-week results of the global Phase 3 trial, “POLARIS-AD,” at the Clinical Trials on Alzheimer's Disease conference (CTAD 2026) in Boston, U.S., on November 16 (local time). The trial enrolled 1,535 patients with early Alzheimer's disease, who took either 30 mg of AR1001 or a placebo once a day.
Before starting the trial, AriBio divided the analysis populations into all 1,535 patients and 604 patients who were not taking existing dementia medications (the monotherapy group). The trial was designed to meet its goal if the score on the primary endpoint, the Clinical Dementia Rating-Sum of Boxes (CDR-SB), improved significantly compared with the placebo group in either of the two populations. The CDR-SB measures both memory and the ability to perform daily activities, scoring the severity of dementia on a scale from 0 to 18.
In the CDR-SB analysis, the primary endpoint, the worsening in scores among patients receiving AR1001 in the monotherapy group was 0.44 points less than in the placebo group. The treatment slowed the rate of symptom worsening by about 31%, with a statistically significant difference. By contrast, the difference in scores in the overall patient population was just 0.11 points (7%), and did not reach statistical significance. Neither group showed a significant difference from the placebo group on the secondary endpoints, which separately assessed cognitive function and the ability to perform daily activities. Asked why the effect was seen only in the monotherapy group, Professor Sha said, “We are still studying that,” adding, “We are all asking the same question right now.”
Compared with existing treatments, AR1001's trial results remain limited. Leqembi and Kisunla, injectable dementia treatments previously approved by the FDA, demonstrated in global Phase 3 trials that they slowed disease progression by 27% and 29%, respectively, compared with placebo in the overall patient population.
Experts are taking a cautious view of the drug's prospects for future approval. “It did not demonstrate efficacy in the overall patient population and showed some potential only in patients who were not taking other dementia medications,” said Kang Sung-hoon, director of strategic research at the Korean Dementia Association and a professor of neurology at Korea University Guro Hospital. He described the results as “partial success.” He added, “Regulators are generally cautious about approval if significant results are not achieved in the overall patient population,” explaining that “it is also an issue whether approval would be limited to patients who are not taking existing treatments.”
Another university hospital professor, who requested anonymity, said, “It is difficult to call the results a success overall, but it is also difficult to conclude that the trial was a complete failure.” The professor added, “An effect was observed in a subgroup of patients, but further analysis is needed to better identify the characteristics of patients who respond to the drug and clarify the clinical significance.”
Some also see significance in the results from the monotherapy group. Kim Sang-yoon, a professor of neurology at Seoul National University Bundang Hospital who participated in the trial and is a former president of the Korean Dementia Association, said the results “should be considered a success.” The findings suggest the potential to develop AR1001 as an early treatment for patients with mild cognitive impairment who have shown a response despite not taking existing dementia medications. “As a rule, existing dementia medications are not prescribed at the mild cognitive impairment stage,” Professor Kim said. “At this stage, we could consider a treatment strategy involving AR1001 as a standalone therapy.” In other words, there may be scope to seek FDA approval by designating patients who are not taking dementia medications as a separate treatment population.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
AR1001 is a drug candidate whose global rights were transferred to China's Fosun Pharma in May 2026 in a deal valued at up to $4.7 billion (approximately 7 trillion won). Most of the upfront payment will be received only if Fosun Pharma exercises its option after reviewing the Phase 3 results. “We received the data last Friday and are continuing to analyze it,” Professor Sha said. “We will present the results of further analyses at a future conference.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.